Skip to main content

Grafa News and Videos — Page 1611

Latest

Grafa

Reviva Pharmaceuticals narrows path to Brilaroxazine FDA submission with 2026 Phase 3 launch

Reviva Pharmaceuticals Holdings (NASDAQ:RVPH), a clinical-stage pharmaceutical company developing next-generation therapies for central nervous system (CNS) disorders, today announced its financial results and corporate updates for the full year ended December 31, 2025.

Read more: Reviva Pharmaceuticals narrows path to Brilaroxazine FDA submission with 2026 Phase 3 launch

GET YOUR GRAFA EDGE NOW

We'll switch on a 30-day Edge trial as a welcome gift